Search CTL/CD8+ T-Cell Epitope Database

Found 9 matching records:

Displaying record number 52088

HXB2 Location	Gag(77-85) p17(77-85) DNA(1018..1044)	Gag Epitope Map
Author Location
Epitope	`SLYNTVATL`	Epitope Alignment
Subtype	B
Species (MHC/HLA)	human(A*0201)
Immunogen	HIV-1 infection
Experimental methods
Keywords	rate of progression, immunodominance

Notes

CTL activity was monitored in 27 individuals, including 10 LTNP with an over-expression of HLA B*5701 -- these individuals have viral loads below the threshold of infection without therapy, and their immune response tends to be focused on peptides that contain B*5701 epitopes ISPRTLNAW, KAFSPEVIPMF, TSTLQEQIGW, and QASQEVKNW.
CTL responses are broader in B*5701+ individuals with progressive viremia than those that control viremia.
The HLA-A*0201 SLYNTVATL epitope response was not as strong in individuals that carried both A2 and B57.

References

Migueles2001 Stephen A. Migueles and Mark Connors. Frequency and Function of HIV-Specific CD8(+) T Cells. Immunol. Lett., 79(1-2):141-150, 1 Nov 2001. PubMed ID: 11595301. Show all entries for this paper.

Displaying record number 52081

HXB2 Location	Gag(147-155) p24(15-23) DNA(1228..1254)	Gag Epitope Map
Author Location
Epitope	`ISPRTLNAW`	Epitope Alignment
Subtype	B
Species (MHC/HLA)	human(B*5701)
Immunogen	HIV-1 infection
Experimental methods
Keywords	rate of progression, immunodominance

Notes

HLA B*5701 was found in a very high frequency in HIV-1 infected non-progressors, 11/13 (85%) versus 19/200 (9.5%) of progressors. Non-progressors tended to have an immune response that was highly focused on four p24 epitopes that were presented by B*5701, ISPRTLNAW, KAFSPEVIPMF, TSTLQEQIGW, and QASQEVKNW.

References

Displaying record number 52085

HXB2 Location	Gag(147-155) p24(15-23) DNA(1228..1254)	Gag Epitope Map
Author Location
Epitope	`ISPRTLNAW`	Epitope Alignment
Subtype	B
Species (MHC/HLA)	human(B*5701)
Immunogen	HIV-1 infection
Experimental methods
Keywords	rate of progression, immunodominance

Notes

CTL activity was monitored in 27 individuals, including 10 LTNP with an over-expression of HLA B*5701 -- these individuals have viral loads below the threshold of infection without therapy, and their immune response tends to be focused on peptides that contain B*5701 epitopes ISPRTLNAW, KAFSPEVIPMF, TSTLQEQIGW, and QASQEVKNW.
CTL responses are broader in B*5701+ individuals with progressive viremia than those that control viremia.
The HLA-A*0201 SLYNTVATL epitope response was not as strong in individuals that carried both A2, B57.

References

Displaying record number 52086

HXB2 Location	Gag(162-172) p24(30-40) DNA(1273..1305)	Gag Epitope Map
Author Location
Epitope	`KAFSPEVIPMF`	Epitope Alignment
Subtype	B
Species (MHC/HLA)	human(B*5701)
Immunogen	HIV-1 infection
Experimental methods
Keywords	rate of progression, immunodominance

Notes

CTL activity was monitored in 27 individuals, including 10 LTNP with an over-expression of HLA B*5701 -- these individuals have viral loads below the threshold of infection without therapy, and their immune response tends to be focused on peptides that contain B*5701 epitopes ISPRTLNAW, KAFSPEVIPMF, TSTLQEQIGW, and QASQEVKNW.
CTL responses are broader in B*5701+ individuals with progressive viremia than those that control viremia.
The HLA-A*0201 SLYNTVATL epitope response was not as strong in individuals that carried both A2 and B57.

References

Displaying record number 52082

HXB2 Location	Gag(162-172) p24(30-40) DNA(1273..1305)	Gag Epitope Map
Author Location
Epitope	`KAFSPEVIPMF`	Epitope Alignment
Subtype	B
Species (MHC/HLA)	human(B*5701)
Immunogen	HIV-1 infection
Experimental methods
Keywords	rate of progression, immunodominance

Notes

HLA B*5701 was found in a very high frequency in HIV-1 infected non-progressors, 11/13 (85%) versus 19/200 (9.5%) of progressors. Non-progressors tended to have an immune response that was highly focused on four p24 epitopes that were presented by B*5701, ISPRTLNAW, KAFSPEVIPMF, TSTLQEQIGW, and QASQEVKNW.
Attempts to make all for HLA B*5701-epitope tetramers were made, but only the HLA B*5701-KAFSPEVIPMF tetramer folded properly. The percentage of CD8+ T cells staining with this HLA B*57 gag tetramer and the fraction of CD69+IFN-+ cells responding to autologous B cells pulsed with KAFSPEVIPMF was highly correlated (r = 0.84; P = 0.005). The percent of CD8+ T cells that stain with the A*2 gag SLYNTVATL tetramer was low (0-0.31%) in a A2+ B57+ LTNP, emphasizing the focus of the immune response on the B*5701 epitopes.

References

Displaying record number 52087

HXB2 Location	Gag(240-249) p24(108-117) DNA(1507..1536)	Gag Epitope Map
Author Location
Epitope	`TSTLQEQIGW`	Epitope Alignment
Subtype	B
Species (MHC/HLA)	human(B*5701)
Immunogen	HIV-1 infection
Experimental methods
Keywords	rate of progression, immunodominance

Notes

CTL activity was monitored in 27 individuals, including 10 LTNP with an over-expression of HLA B*5701 -- these individuals have viral loads below the threshold of infection without therapy, and their immune response tends to be focused on peptides that contain B*5701 epitopes ISPRTLNAW, KAFSPEVIPMF, TSTLQEQIGW, and QASQEVKNW.
CTL responses are broader in B*5701+ individuals with progressive viremia than those that control viremia.
The HLA-A*0201 SLYNTVATL epitope response was not as strong in individuals that carried both A2, B57.

References

Displaying record number 52083

HXB2 Location	Gag(240-249) p24(108-117) DNA(1507..1536)	Gag Epitope Map
Author Location
Epitope	`TSTLQEQIGW`	Epitope Alignment
Subtype	B
Species (MHC/HLA)	human(B*5701)
Immunogen	HIV-1 infection
Experimental methods
Keywords	rate of progression, immunodominance

Notes

HLA B*5701 was found in a very high frequency in HIV-1 infected non-progressors, 11/13 (85%) versus 19/200 (9.5%) of progressors. Non-progressors tended to have an immune response that was highly focused on four p24 epitopes that were presented by B*5701, ISPRTLNAW, KAFSPEVIPMF, TSTLQEQIGW, and QASQEVKNW.

References

Displaying record number 52084

HXB2 Location	Gag(308-316) p24(176-184) DNA(1711..1737)	Gag Epitope Map
Author Location
Epitope	`QASQEVKNW`	Epitope Alignment
Subtype	B
Species (MHC/HLA)	human(B*5701)
Immunogen	HIV-1 infection
Experimental methods
Keywords	rate of progression, immunodominance

Notes

HLA B*5701 was found in a very high frequency in HIV-1 infected non-progressors, 11/13 (85%) versus 19/200 (9.5%) of progressors. Non-progressors tended to have an immune response that was highly focused on four p24 epitopes that were presented by B*5701, ISPRTLNAW, KAFSPEVIPMF, TSTLQEQIGW, and QASQEVKNW.
Only QASQEVKNW was recognized in all of the LTNP's tested.

References

Displaying record number 52089

HXB2 Location	Gag(308-316) p24(176-184) DNA(1711..1737)	Gag Epitope Map
Author Location
Epitope	`QASQEVKNW`	Epitope Alignment
Subtype	B
Species (MHC/HLA)	human(B*5701)
Immunogen	HIV-1 infection
Experimental methods
Keywords	rate of progression, immunodominance

Notes

CTL activity was monitored in 27 individuals, including 10 LTNP with an over-expression of HLA B*5701 -- these individuals have viral loads below the threshold of infection without therapy, and their CD8+ T-cell response tends to be focused on peptides that contain B*5701 epitopes ISPRTLNAW, KAFSPEVIPMF, TSTLQEQIGW, or QASQEVKNW.
CTL responses are broader in B*5701+ individuals with progressive viremia than those that control viremia.
The HLA-A*0201 SLYNTVATL epitope response was not as strong individuals that carried both A2, B57.